Optimer Announces that the FDA's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection

Optimer Pharmaceuticals, Inc.

announced today that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee recommended that the FDA approve Optimer's investigational antibiotic DIFICID for the treatment of patients with Clostridium difficile infection, a bacterial infection in the lining of the gut that can cause severe diarrhea, colitis and in some cases death. In a unanimous 13-0 decision, the AIDAC found that the clinical evidence submitted by Optimer demonstrated the safety and effectiveness of DIFICID for the treatment of CDI.